Literature DB >> 28486240

Dependence Stage and Pharmacoeconomic Outcomes in Patients With Alzheimer Disease.

Tzeyu L Michaud1, Robin High, Mary E Charlton, Daniel L Murman.   

Abstract

The level of assistance patients with Alzheimer disease (AD) require in their care may be an important predictor of resource use, costs of care, and quality of life. The Dependence Scale (DS), a measure of care-assistance required, was used to estimate costs of care and quality of life of patients with AD categorized into 6 dependence stages based upon the summated item scores of the DS. Data were derived from a 3-year, noninterventional study of 132 patients with probable AD (ages, 50 to 85 y) and caregiver dyads. We investigated the association between DS scores and health care costs, health-related quality of life (HRQoL), caregiver burden and estimated annual costs and HRQoL for 6 dependence stages in adjusted models. DS scores were significant predictors of health care costs, HRQoL, and caregiver burden. The estimated annual health care costs and a measure of HRQoL (EuroQoL-5D) ranged from $11,418 and 1.00 for those at very mild dependence stage to $101,715 and 0.26 for those at very severe dependence stage. DS scores classified into 6 dependence stages provides a useful method to estimate unique levels of care-associated costs and health utilities for pharmacoeconomic evaluations of new treatments for AD.

Entities:  

Mesh:

Year:  2017        PMID: 28486240      PMCID: PMC5568933          DOI: 10.1097/WAD.0000000000000198

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  48 in total

1.  Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare.

Authors:  J W Hill; R Futterman; S Duttagupta; V Mastey; J R Lloyd; H Fillit
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Dependence scale for Alzheimer's disease: relationship with other clinical indicators and psychometric properties.

Authors:  Josep Garre-Olmo; Joan Vilalta-Franch; Laia Calvó-Perxas; Sílvia Monserrat-Vila; Secundino López-Pousa
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-10-20       Impact factor: 2.680

4.  Association between illness progression measures and total cost in Alzheimer's disease.

Authors:  L A Lacey; T Niecko; C Leibman; E Liu; M Grundman
Journal:  J Nutr Health Aging       Date:  2013-09       Impact factor: 4.075

5.  The screen for caregiver burden.

Authors:  P P Vitaliano; J Russo; H M Young; J Becker; R D Maiuro
Journal:  Gerontologist       Date:  1991-02

Review 6.  Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.

Authors:  Kaycee M Sink; Karen F Holden; Kristine Yaffe
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

7.  Factors related to perceived quality of life in patients with Alzheimer's disease: the patient's perception compared with that of caregivers.

Authors:  Josep Lluís Conde-Sala; Josep Garre-Olmo; Oriol Turró-Garriga; Secundino López-Pousa; Joan Vilalta-Franch
Journal:  Int J Geriatr Psychiatry       Date:  2009-06       Impact factor: 3.485

Review 8.  The stage specific temporal course of Alzheimer's disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation.

Authors:  B Reisberg; S H Ferris; M J de Leon; A Kluger; E Franssen; J Borenstein; R C Alba
Journal:  Prog Clin Biol Res       Date:  1989

9.  Psychometric properties of the Dependence Scale in large randomized clinical trials of patients with mild and moderate Alzheimer's disease.

Authors:  Kathleen W Wyrwich; Priscilla Auguste; Jacqui Buchanan; Katja Rudell; Loretto Lacey; Christopher Leibman; Tara Symonds; H Robert Brashear
Journal:  Am J Alzheimers Dis Other Demen       Date:  2014-04-15       Impact factor: 2.035

10.  The validity of dependence as a health outcome measure in Alzheimer's disease.

Authors:  D Eldon Spackman; Srikanth Kadiyala; Peter J Neumann; David L Veenstra; Sean D Sullivan
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-03-19       Impact factor: 2.035

View more
  3 in total

1.  Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.

Authors:  Eric L Ross; Marc S Weinberg; Steven E Arnold
Journal:  JAMA Neurol       Date:  2022-05-01       Impact factor: 29.907

Review 2.  The Humanistic and Economic Burden of Alzheimer's Disease.

Authors:  Amir Abbas Tahami Monfared; Michael J Byrnes; Leigh Ann White; Quanwu Zhang
Journal:  Neurol Ther       Date:  2022-02-22

3.  Alzheimer's Treatment: Real-World Physician Behavior Across Countries.

Authors:  Jana Podhorna; Nadine Winter; Hartmut Zoebelein; Thomas Perkins
Journal:  Adv Ther       Date:  2020-01-13       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.